Markets:

Overview

News

Currencies

International

Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

114.51 +0.12 (+0.10%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Why Is Blood Cancer Focused Arcellx Stock Trading Higher Today? ↗

November 02, 2023

Arcellx Inc (NASDAQ: ACLX) announced that new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refra

Via Benzinga

Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday ↗

November 02, 2023

U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

7 Biotech Stocks to Get In Now Before Investors Catch On ↗

October 23, 2023

Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.

Via InvestorPlace

Analyst Ratings for Arcellx ↗

June 20, 2023

Via Benzinga

Why Arcellx (ACLX) Stock Is Nosediving ↗

June 20, 2023

Arcellx Inc (NASDAQ: ACLX) shares are trading lower by 8.50% to $32.76 Tuesday morning after the FDA on Monday put a clinical hold on the company's multiple myeloma phase 2 trial.

Via Benzinga

The Latest Analyst Ratings for Arcellx ↗

May 18, 2023

Via Benzinga

Where Arcellx Stands With Analysts ↗

April 24, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗

October 17, 2023

Via Benzinga

What 5 Analyst Ratings Have To Say About Arcellx ↗

March 30, 2023

Via Benzinga

Where Arcellx Stands With Analysts ↗

December 12, 2022

Via Benzinga

Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs ↗

October 02, 2023

CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T.

Via InvestorPlace

Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential ↗

August 15, 2023

The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 Clinical Program.

Via Benzinga

FDA Gives Green Signal To Arcellx's Stopped Blood Cancer Study ↗

August 15, 2023

The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 14, 2023

Via Benzinga

Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death ↗

June 20, 2023

A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex.

Via Investor's Business Daily

Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

June 20, 2023

Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740.

Via Benzinga

Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls ↗

June 20, 2023

The FDA has put a clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 clinical program for CART-ddBCMA investigational new drug for

Via Benzinga

Why Cano Health Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket ↗

June 20, 2023

Gainers

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

June 20, 2023

It's time for another dive into the biggest pre-market stock movers as we check out all the latest news for Tuesday morning!

Via InvestorPlace

Alibaba, Arcellx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

June 20, 2023

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023 ↗

May 18, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2023 ↗

April 14, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023 ↗

March 14, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023 ↗

February 13, 2023

Via Benzinga

Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

January 30, 2023

From Gilead Sciences, Inc. and Arcellx, Inc.

Via Business Wire

20 Favorite Biotech & Medical Stocks For 2023 ↗

December 28, 2022

The way these stocks are setting up, many of them look great and will be at the forefront this coming year.

Via Talk Markets

Dow Tumbles 100 Points; Silver Rises Over 2% ↗

December 09, 2022

U.S. stocks traded mostly lower toward the end of trading with the Dow Jones dropping 100 points on Friday

Via Benzinga

US Stocks Turn Higher; Nasdaq Rises 40 Points ↗

December 09, 2022

U.S. stocks traded slightly midway through trading with the Nasdaq gaining over 40 points on Friday

Via Benzinga

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗

December 19, 2022

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

Via Benzinga

Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session ↗

December 09, 2022

Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.